11:00 Chairperson’s Opening
Dominic Clarke, Chief Technical Officer, DLS

11:05 A New Approach to Treating Cancer – miCAR Cellular Engineering (Live-Stream)

• Allo constructs for cell based therapies in cancer are evolving to deliver, safety, efficacy and persistence
• We will describe the utilisation of Antion’s miCAR platform to engineer the most efficient cells

Sven Kili, Chief Executive Officer, Antion Biosciences SA

11:20 Effective Donor Sourcing Strategies to Enhance Downstream Efficiency and Scalability of Allogeneic Cell Therapies

• Examining the impact of inter-donor variability of cellular source material
• How streamlined donor management can improve outcomes utilizing inherently variable starting material for manufacture of off-the-shelf therapies
• Benchmarking how raw material supply partners can help mitigate risk and provide sustainable growth strategies to overcome supply chain hurdles – a case study

Kimberly Negrin, Director, Cell Therapy Strategy and Business Operations, Charles River Laboratories 

11:35 Tackling Antigen Escape & Manufacturing Cost for Cell Therapies

• Will review novel BAFF Ligand CAR with 3 antigens on a single CAR
• Will review dynamic Antigen programming approach
• Will review allogenic approaches to Cell Therapies

Jeff Liter, Chief Executive Officer, Luminary Therapeutics

11:50 Cell Therapy Media: A New Paradigm

• Cell Therapy Media directly impacts therapeutic potency
• Historically limited options for creating Media optimized to your ecosystem and CQA’s
• We present a novel paradigm for owning, configuring and ordering your media from bench to bioreactor

David Sheehan, Founder, President and Chief Executive Officer, Nucleus Biologics

12:05 Speaker Q&A and Panel Discussion